Arch Therapeutics Inc (ARTH)

[Polyphemus]

In response to your question: (1) European Commission has really screwed things up. US government has written to EU and stated that the NB issue threatens to interfere with international trade, and asked for a 3 year postponement for NB changes: no response to date. Other comments, not solicited: (2) European markets are generally more price sensitive than in US and more fragmented. Really difficult for a small manufacturer with a narrow product line to have a positive effect, especially in crowded markets. Hard to see how commercializatiion in Europe will be cash positive and contribute to the development of a valuable surgical product. (3) Look at the more careful language in ARTH slides for the recent Wainwright conference; several important changes in posture that may be significant: ARTH: AC5 to seal and protect bleeding, leaking and injured tissues. Also: AC5 mechanism of action is stated as control the movement of fluids and substances while enabling healing. AC5 is not depicted as a hemostat that accelerates the process of clotting, but as a sealant. This is not the only significant change. Are these accidents? Your call.